<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663946</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-8MK</org_study_id>
    <nct_id>NCT03663946</nct_id>
  </id_info>
  <brief_title>A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread</brief_title>
  <official_title>Drug Use Investigation on Combination Therapy With Yervoy and Opdivo (Unresectable or Metastatic Renal Cell Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment
      for the first time with Yervoy and Opdivo in the real world
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of immune-related AE's</measure>
    <time_frame>Approximately 13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of immune related SAE's</measure>
    <time_frame>Approximately 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment for immune-related adverse reactions</measure>
    <time_frame>Approximately 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unknown AE's</measure>
    <time_frame>Approximately 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unknown SAE's</measure>
    <time_frame>Approximately 13 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Patients taking combination therapy with Yervoy and Opdivo</arm_group_label>
    <description>Medical records will be reviewed for safety and treatments for specific ADR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Patients taking combination therapy with Yervoy and Opdivo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment
        for the first time with Yervoy and Opdivo
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable or metastatic renal cell carcinoma who are initiating
             treatment for the first time with Yervoy and Opdivo in accordance with the Japanese
             package insert will be included in this PMS

        Exclusion Criteria:

          -  Patients receiving combination therapy with Yervoy and Opdivo for non RCC indication
             will be excluded from this PMS

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <zip>170-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

